{
    "clinical_study": {
        "@rank": "35182", 
        "arm_group": [
            {
                "arm_group_label": "1: Tramadol HCl 200 mg daily or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered."
            }, 
            {
                "arm_group_label": "2: Tramadol HCl 400 mg daily or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered."
            }, 
            {
                "arm_group_label": "3: Tramadol HCl 600 mg daily or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability profile of tramadol\n      hydrochloride (HCl) given as oral doses every 6 hours, within the range of dosages supported\n      by currently available toxicology and clinical data (200 mg to 600 mg per day)."
        }, 
        "brief_title": "A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a randomized (study drug assigned by chance), sequential-cohort (time lagged),\n      double-blind (neither the participant or the study doctor will know the name of the assigned\n      treatment), parallel-group, placebo-controlled, 3-arm (participants will be assigned to 1 of\n      3 treatment groups), single-center, Phase 1 study of multiple ascending doses of tramadol\n      HCl in healthy adult volunteers. Thirty participants (15 men and 15 women) will be\n      sequentially assigned to 1 of 3 treatment groups of 10 subjects each (5 men and 5 women).\n      Participants in each treatment group will receive a total of 9 oral doses (one every 6\n      hours) of tramadol HCl or placebo, in the ratio of 4:1. The study includes a screening phase\n      and a double-blind treatment phase. The treatment phase will consist of 3 treatment periods\n      separated by a 5-day safety review period before the next ascending dose of study drug is\n      administered to the next group. Participants in each group will be confined to the study\n      center for a total of 5 days, the total duration of each subject's participation will be up\n      to 33 days, including the screening phase. The total duration of the study (completion of\n      all 3 treatment cohorts) will be up-to-approximately 2 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  body mass index between 18 and 30 kg/m\u00b2, inclusive\n\n          -  body weight not less than 50 kg\n\n          -  have a normal electroencephalogram under basic and stimulated conditions\n\n          -  have a 12-lead ECG that is consistent with normal cardiac conduction and function\n\n          -  have not used any tobacco products (eg, cigarettes, cigars, chewing tobacco, gum, or\n             patch) for at least 6 months before first study drug administration\n\n        Exclusion Criteria:\n\n          -  any personal or family history of epileptic seizures or convulsions\n\n          -  have suffered from head trauma with loss of consciousness -have suffered from central\n             nervous system infection\n\n          -  have suffered from loss of consciousness of unknown origin\n\n          -  drowning or sudden infant death syndrome in a first degree relative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947920", 
            "org_study_id": "CR102458", 
            "secondary_id": [
                "TRAMPAI1002", 
                "V01-TRAA-501", 
                "2013-01-00"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1: Tramadol HCl 200 mg daily or placebo", 
                    "2: Tramadol HCl 400 mg daily or placebo", 
                    "3: Tramadol HCl 600 mg daily or placebo"
                ], 
                "description": "50-mg overencapsulated tablet for oral administration", 
                "intervention_name": "Tramadol HCl, 50 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1: Tramadol HCl 200 mg daily or placebo", 
                    "2: Tramadol HCl 400 mg daily or placebo", 
                    "3: Tramadol HCl 600 mg daily or placebo"
                ], 
                "description": "Size-matching capsules containing an appropriate inactive excipient", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tramadol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Pain", 
            "Tramadol hydrochloride", 
            "Tramadol HCl", 
            "Analgesic", 
            "QT prolongation", 
            "RWJ-26898-002"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Following Multiple Ascending Doses of Tramadol Hydrochloride in Healthy Male and Female Subjects", 
        "overall_official": {
            "affiliation": "Janssen Scientific Affairs, LLC", 
            "last_name": "Janssen Scientific Affairs, LLC Clinical trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Changes in clinical laboratory results, vital signs, psycopharmacologic status (Richmond Agitation-Sedation Scale (RASS), and physical examination.", 
            "measure": "Change from baseline in vital signs and other parameters as a measure of safety and tolerability of tramadol", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, Days 1 through 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ECG will detect abnormal changes from baseline in cardiac depolarization/repolarization.", 
                "measure": "Change from baseline in time-matched electrocardiogram (ECG) measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1, Day 3 and Day 4"
            }, 
            {
                "description": "Determination of concentrations of tramadol and M1 metabolite pharmacokinetic parameters in venous plasma.", 
                "measure": "Change from baseline in pharmacokinetic parameters of tramadol and M1 metabolite", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 72 hours after the 1st dose"
            }, 
            {
                "measure": "Incidence and type of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, till the end of study"
            }
        ], 
        "source": "Janssen Scientific Affairs, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Valeant Pharmaceuticals International Inc, Cipher Pharmaceuticals Inc", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Janssen Scientific Affairs, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}